180 related articles for article (PubMed ID: 27365203)
21. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
[TBL] [Abstract][Full Text] [Related]
22. Optimum resource allocation to reduce HIV incidence across sub-Saharan Africa: a mathematical modelling study.
McGillen JB; Anderson SJ; Dybul MR; Hallett TB
Lancet HIV; 2016 Sep; 3(9):e441-e448. PubMed ID: 27562745
[TBL] [Abstract][Full Text] [Related]
23. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
[TBL] [Abstract][Full Text] [Related]
24. The effect of 90-90-90 on HIV-1 incidence and mortality in eSwatini: a mathematical modelling study.
Akullian A; Morrison M; Garnett GP; Mnisi Z; Lukhele N; Bridenbecker D; Bershteyn A
Lancet HIV; 2020 May; 7(5):e348-e358. PubMed ID: 32061317
[TBL] [Abstract][Full Text] [Related]
25. Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA.
Adamson B; Garrison L; Barnabas RV; Carlson JJ; Kublin J; Dimitrov D
J Int AIDS Soc; 2019 Aug; 22(8):e25373. PubMed ID: 31402591
[TBL] [Abstract][Full Text] [Related]
26. PrEP as a feature in the optimal landscape of combination HIV prevention in sub-Saharan Africa.
McGillen JB; Anderson SJ; Hallett TB
J Int AIDS Soc; 2016; 19(7(Suppl 6)):21104. PubMed ID: 27760682
[TBL] [Abstract][Full Text] [Related]
27. Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study.
Marshall BDL; Goedel WC; King MRF; Singleton A; Durham DP; Chan PA; Townsend JP; Galvani AP
Lancet HIV; 2018 Sep; 5(9):e498-e505. PubMed ID: 29908917
[TBL] [Abstract][Full Text] [Related]
28. Acceptability of microbicidal vaginal rings and oral pre-exposure prophylaxis for HIV prevention among female sex workers in a high-prevalence US city.
Peitzmeier SM; Tomko C; Wingo E; Sawyer A; Sherman SG; Glass N; Beyrer C; Decker MR
AIDS Care; 2017 Nov; 29(11):1453-1457. PubMed ID: 28271718
[TBL] [Abstract][Full Text] [Related]
29. Beyond the 90-90-90: refocusing HIV prevention as part of the global HIV response.
Baggaley R; Dalal S; Johnson C; Macdonald V; Mameletzis I; Rodolph M; Figueroa C; Samuelson J; Verster A; Doherty M; Hirnschall G
J Int AIDS Soc; 2016; 19(1):21348. PubMed ID: 27989271
[TBL] [Abstract][Full Text] [Related]
30. Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa?
Verguet S; Stalcup M; Walsh JA
Sex Transm Infect; 2013 Dec; 89(8):628-34. PubMed ID: 23912819
[TBL] [Abstract][Full Text] [Related]
31. HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project.
Eakle R; Gomez GB; Naicker N; Bothma R; Mbogua J; Cabrera Escobar MA; Saayman E; Moorhouse M; Venter WDF; Rees H;
PLoS Med; 2017 Nov; 14(11):e1002444. PubMed ID: 29161256
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058.
van de Vijver DAMC; Richter AK; Boucher CAB; Gunsenheimer-Bartmeyer B; Kollan C; Nichols BE; Spinner CD; Wasem J; Schewe K; Neumann A
Euro Surveill; 2019 Feb; 24(7):. PubMed ID: 30782266
[TBL] [Abstract][Full Text] [Related]
33. The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa.
Quaife M; Terris-Prestholt F; Eakle R; Cabrera Escobar MA; Kilbourne-Brook M; Mvundura M; Meyer-Rath G; Delany-Moretlwe S; Vickerman P
J Int AIDS Soc; 2018 Mar; 21(3):. PubMed ID: 29537654
[TBL] [Abstract][Full Text] [Related]
34. Maximizing the benefits of ART and PrEP in resource-limited settings.
Akudibillah G; Pandey A; Medlock J
Epidemiol Infect; 2017 Apr; 145(5):942-956. PubMed ID: 28031062
[TBL] [Abstract][Full Text] [Related]
35. The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study.
Bórquez A; Guanira JV; Revill P; Caballero P; Silva-Santisteban A; Kelly S; Salazar X; Bracamonte P; Minaya P; Hallett TB; Cáceres CF
Lancet Public Health; 2019 Mar; 4(3):e127-e136. PubMed ID: 30683587
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of voluntary medical male circumcision for HIV prevention across sub-Saharan Africa: results from five independent models.
Bansi-Matharu L; Mudimu E; Martin-Hughes R; Hamilton M; Johnson L; Ten Brink D; Stover J; Meyer-Rath G; Kelly SL; Jamieson L; Cambiano V; Jahn A; Cowan FM; Mangenah C; Mavhu W; Chidarikire T; Toledo C; Revill P; Sundaram M; Hatzold K; Yansaneh A; Apollo T; Kalua T; Mugurungi O; Kiggundu V; Zhang S; Nyirenda R; Phillips A; Kripke K; Bershteyn A
Lancet Glob Health; 2023 Feb; 11(2):e244-e255. PubMed ID: 36563699
[TBL] [Abstract][Full Text] [Related]
37. Scaling up circumcision programs in Southern Africa: the potential impact of gender disparities and changes in condom use behaviors on heterosexual HIV transmission.
Andersson KM; Owens DK; Paltiel AD
AIDS Behav; 2011 Jul; 15(5):938-48. PubMed ID: 20924783
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study.
Phillips AN; Bershteyn A; Revill P; Bansi-Matharu L; Kripke K; Boily MC; Martin-Hughes R; Johnson LF; Mukandavire Z; Jamieson L; Meyer-Rath G; Hallett TB; Ten Brink D; Kelly SL; Nichols BE; Bendavid E; Mudimu E; Taramusi I; Smith J; Dalal S; Baggaley R; Crowley S; Terris-Prestholt F; Godfrey-Faussett P; Mukui I; Jahn A; Case KK; Havlir D; Petersen M; Kamya M; Koss CA; Balzer LB; Apollo T; Chidarikire T; Mellors JW; Parikh UM; Godfrey C; Cambiano V;
Lancet HIV; 2022 May; 9(5):e353-e362. PubMed ID: 35489378
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and cost-effectiveness of early antiretroviral therapy and partners' pre-exposure prophylaxis among men who have sex with men in Shenyang, China: a prospective cohort and costing study.
Hu QH; Meyers K; Xu JJ; Chu ZX; Zhang J; Ding HB; Han XX; Jiang YJ; Geng WQ; Shang H
BMC Infect Dis; 2019 Jul; 19(1):663. PubMed ID: 31345169
[TBL] [Abstract][Full Text] [Related]
40. Healthcare providers' understanding of HIV serodiscordance in South Africa and Uganda: implications for HIV prevention in sub-Saharan Africa.
Greener R; Milford C; Bajunirwe F; Mosery FN; Ng CK; Rifkin R; Kastner J; Pillay L; Kaida A; Bangsberg DR; Smit JA; Matthews LT
Afr J AIDS Res; 2018 Jul; 17(2):137-144. PubMed ID: 29745290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
